CGEM vs. CNTA, HCM, KYMR, BHC, VERA, PTGX, BEAM, HRMY, CGON, and JANX
Should you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Centessa Pharmaceuticals (CNTA), HUTCHMED (HCM), Kymera Therapeutics (KYMR), Bausch Health Companies (BHC), Vera Therapeutics (VERA), Protagonist Therapeutics (PTGX), Beam Therapeutics (BEAM), Harmony Biosciences (HRMY), CG Oncology (CGON), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.
Cullinan Therapeutics vs.
Centessa Pharmaceuticals (NASDAQ:CNTA) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
Centessa Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cullinan Therapeutics received 12 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 82.69% of users gave Cullinan Therapeutics an outperform vote while only 58.49% of users gave Centessa Pharmaceuticals an outperform vote.
In the previous week, Centessa Pharmaceuticals had 5 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 7 mentions for Centessa Pharmaceuticals and 2 mentions for Cullinan Therapeutics. Centessa Pharmaceuticals' average media sentiment score of 0.34 beat Cullinan Therapeutics' score of 0.32 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.
82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 11.6% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Centessa Pharmaceuticals has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500.
Cullinan Therapeutics' return on equity of -26.54% beat Centessa Pharmaceuticals' return on equity.
Centessa Pharmaceuticals presently has a consensus price target of $25.83, suggesting a potential upside of 55.34%. Cullinan Therapeutics has a consensus price target of $32.50, suggesting a potential upside of 259.91%. Given Cullinan Therapeutics' higher possible upside, analysts clearly believe Cullinan Therapeutics is more favorable than Centessa Pharmaceuticals.
Summary
Centessa Pharmaceuticals and Cullinan Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Cullinan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cullinan Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CGEM) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CGEM Stock Alerts